InflammX Therapeutics
PrivateLast Round
VC Round
Mar 15, 2026
Total Funding Raised
$67.95M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
InflammX Therapeutics is a clinical-stage biopharmaceutical company developing Xiflam, an orally administered small molecule to treat retinal diseases such as the dry form of age-related macular degeneration (AMD).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
InflammX Therapeutics Comparables
Compare InflammX Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AltRegen | 74% | |
| Belite Bio, Inc | 73% | |
| Alkeus Pharmaceuticals | 71% |
InflammX Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Mar 15, 2026 | ||||
| Series A | Jan 10, 2025 | ||||
| Series B | Jul 24, 2012 | ||||
| Series A | Sep 25, 2008 |
InflammX Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RusnanoMedInvest | Series B |
| National Eye Institute (NIH) | Grant |
| Domain Associates | Series B, Series A |
| GBS Venture Partners | Series B, Series A |
| JDRF | Grant |
| BioPacificVentures | Series A, Series B |
| ExSight Ventures | Series A, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 22, 2026
Monthly visitors increased 375% MoM to 1.3K.
- Mar 15, 2026
Raised a VC Round with ExSight Ventures participating.
InflammX Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about InflammX Therapeutics's valuation, stock price, and market status.
Is InflammX Therapeutics a public or private company?
InflammX Therapeutics is a private company.
What is the current stock price of InflammX Therapeutics?
InflammX Therapeutics is a private company, so its shares have no public market price. Caplight tracks InflammX Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is InflammX Therapeutics worth (valuation)?
Valuation information for InflammX Therapeutics is not publicly available.
Can I buy InflammX Therapeutics stock?
InflammX Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was InflammX Therapeutics's last funding round?
InflammX Therapeutics's most recent funding round was VC Round on March 15, 2026.
Who are the main investors in InflammX Therapeutics?
Key investors in InflammX Therapeutics include Domain Associates, GBS Venture Partners.
Will InflammX Therapeutics IPO soon?
No public IPO plans have been announced for InflammX Therapeutics.
How can I track InflammX Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in InflammX Therapeutics's shares on secondary markets.